New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy

References

• LundstromKBoulikasTViral and non-viral vectors in gene therapy: technology development and clinical trialsTechnol Cancer Res Treat2003247148614529313
   PubMed Web of Science ®Google Scholar
• RaperSEChirmuleNLeeFSFatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transferMol Genet Metab20038014815814567964
   PubMed Web of Science ®Google Scholar
• McCormackMPRabbittsTHActivation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiencyN Engl J Med200435091392214985489
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-AbinaSGarrigueAWangGPInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1J Clin Invest20081183132314218688285
   PubMed Web of Science ®Google Scholar
• TsengJCDanielsGMerueloDControlled propagation of replication-competent Sindbis viral vector using suicide gene strategyGene Ther20091629129618818670
   PubMed Web of Science ®Google Scholar
• LundstromKLatest trends in cancer therapy applying viral vectorsFuture Virol201712667684
   Web of Science ®Google Scholar
• LinYZhangHLiangJIdentification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancersProc Natl Acad Sci U S A2014111E4504E451225288727
   PubMed Web of Science ®Google Scholar
• LinENemunaitisJOncolytic viral therapiesCancer Gene Ther20041164366415286681
   PubMed Web of Science ®Google Scholar
• KaufmanHLKohlhappFJZlozaAOncolytic viruses: a new class of immunotherapy drugsNat Rev Drug Discov20151464266226323545
   PubMed Web of Science ®Google Scholar
• YoungBASpencerJFYingBTollefsonAETothKWoldWSThe role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumorsCancer Gene Ther20132052153023928731
   PubMed Web of Science ®Google Scholar
• LiJMKaoKCLiLFMicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small lung cancer cellsVirol J20131024123876001
   PubMed Web of Science ®Google Scholar
• MurphyAMBesmerDMMoerdyk-SchauweckerMVesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinomaJ Virol2012863073308722238308
   PubMed Web of Science ®Google Scholar
• ZhaoLLiuHNewcastle disease virus: a promising agent for tumor immunotherapyClin Exp Pharmacol Physiol20123972573022211810
   PubMed Web of Science ®Google Scholar
• EhrigKKilincMOChenNGGrowth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68J Transl Med2013117923531320
   PubMed Web of Science ®Google Scholar
• LundstromKNew era in gene therapySinghMSalnikovaMNovel Approaches and Strategies for Biologics, Vaccines and Cancer TherapiesLondonAcademic Press20151337
   Google Scholar
• LundstromKOncolytic alphaviruses in cancer immunotherapyVaccines201759
   Web of Science ®Google Scholar
• LiDXuDWangZImmunogenicity evaluation of modified adenovirus vaccines expressing porcine circovirus type 2 capsid protein in pigsViral Immunol20173011111927996636
   PubMed Web of Science ®Google Scholar
• GriegerJCSamulskiRJPackaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and post-entry stepsJ Virol2005799933994416014954
   PubMed Web of Science ®Google Scholar
• FountzilasCPatelSMahalingamDReview: oncolytic virotherapy, updates and future directions2017 Available from: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=18309&path[]=58706Accessed November 23, 2017
   Google Scholar
• AlainTKimTSLunXProteolytic disassembly is a critical determinant for reovirus oncolysisMol Ther2007151512152117519890
   PubMed Web of Science ®Google Scholar
• MarcatoPShmulevitzMPanDStoltzDLeePWRas transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent releaseMol Ther2007151522153017457318
   PubMed Web of Science ®Google Scholar
• StrongJECoffeyMCTangDSabininPLeePWThe molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirusEMBO J199817335133629628872
   PubMed Web of Science ®Google Scholar
• JamiesonATGentryGASubak-SharpeJHInduction of both thymidine and deoxycytidine kinase activity by herpes virusesJ Gen Virol1974244654804372299
   PubMed Web of Science ®Google Scholar
• VerheijeMHRottierPJRetargeting of viruses to generate oncolytic agentsAdv Virol2012201279852622312365
   PubMedGoogle Scholar
• PrestwichRJErringtonFIlettEJTumor infection by oncolytic reovirus primes adaptive antitumor immunityClin Cancer Res2008147358736619010851
   PubMed Web of Science ®Google Scholar
• TodaMRabkinSDKojimaHMartuzaRLHerpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunityHum Gene Ther19991038539310048391
   PubMed Web of Science ®Google Scholar
• ThorneSHContagCHIntegrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based deliveryGene Ther20081575375818356814
   PubMed Web of Science ®Google Scholar
• DiaconuICerulloVHirvinenMLImmune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirusCancer Res2012722327233822396493
   PubMed Web of Science ®Google Scholar
• MiyamotoSInoueHNakamuraTCoxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinomaCancer Res2012722609262122461509
   PubMed Web of Science ®Google Scholar
• DonnellyOGErrington-MaisFSteeleLMeasles virus causes immunogenic cell death in human melanomaGene Ther20132071522170342
   PubMed Web of Science ®Google Scholar
• CassadyKAHaworthKBJacksonJMarkertJMCripeTPTo infection and beyond: the multi-prolonged anti-cancer mechanisms of oncolytic virusesViruses2016843
   Web of Science ®Google Scholar
• ChioccaEAThe host response to cancer virotherapyCurr Opin Mol Ther200810384518228180
   PubMed Web of Science ®Google Scholar
• HuangJHZhangSNChoiKJTherapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBLMol Ther20101826427419738604
   PubMed Web of Science ®Google Scholar
• MelchjorsenJSørensenLNPaludanSRExpression and function of chemokines during viral infections: from molecular mechanisms to in vivo functionJ Leukoc Biol20037433134312949236
   PubMed Web of Science ®Google Scholar
• WickhamSLuBAshJCarrDJChemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitisJ Neuroimmunol2005162515915833359
   PubMed Web of Science ®Google Scholar
• AghiMChouTCSulingKBreakefieldXOChioccaEAMultimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapiesCancer Res1999593861386510463570
   PubMed Web of Science ®Google Scholar
• BeugSTTangVALaCasseECSmac mimetics and innate immune stimuli synergize to promote tumor deathNat Biotechnol20143218219024463573
   PubMed Web of Science ®Google Scholar
• WongRJPatelSGKimSCytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinomaHum Gene Ther20011225326511177562
   PubMed Web of Science ®Google Scholar
• ChoiIKLeeJSZhangSNOncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18RαGene Ther20111889890921451575
   PubMed Web of Science ®Google Scholar
• ParkerJNMelethSHughesKBGillespieGYWhitleyRJMarkertJMEnhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12Cancer Gene Ther20051235936815678154
   PubMed Web of Science ®Google Scholar
• MillerCGFraserNWRequirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma modelMol Ther2003774174712788647
   PubMed Web of Science ®Google Scholar
• ChioccaEAThe host response to cancer virotherapyCurr Opin Mol Ther200810384518228180
   PubMed Web of Science ®Google Scholar
• WatersAMJohnstonJMReddyATRationale and design of a phase 1 clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant supratentorial brain tumorsHum Gene Ther Clin Dev20172871628319448
   PubMed Web of Science ®Google Scholar
• MatthewsKSAlvarezRDCurielDTAdvancements in adenoviral-based virotherapy for ovarian cancerAdv Drug Deliv Rev20096183684119422865
   PubMed Web of Science ®Google Scholar
• EkbladMHaldenGAdenovirus-based therapy for prostate cancerCurr Opin Mol Ther200912421431
   Google Scholar
• ZhangYZhangBCZhangARCo-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancerOncol Rep2013301989199523933826
   PubMed Web of Science ®Google Scholar
• FuYJDuJYangRJYinLTLiangAHPotential adenovirus-mediated gene therapy of glioma cancerBiotechnol Lett201032111819784809
   PubMed Web of Science ®Google Scholar
• FujiwaraTA novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancerActa Med Okoyama201165151162
   PubMed Web of Science ®Google Scholar
• ShapiraSShapiraAKazanovDHevroniGKrausSArberNSelective eradication of cancer cells by delivery of adenovirus-based toxinsOncotarget20178385813859128445136
   PubMedGoogle Scholar
• ZhouWDaiSZhuHTelomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancerGene Ther20172419920728075429
   PubMed Web of Science ®Google Scholar
• ChoiJWLeeJSKimSWEvolution of oncolytic adenoviruses for cancer treatmentAdv Drug Deliv Rev20126472072922212901
   PubMed Web of Science ®Google Scholar
• ChenJGaoPYuanSOncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer therapyACS Nano201610115481156027977128
   PubMed Web of Science ®Google Scholar
• LiYZhuoBYinYAnti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cellsBiochem Biophys Res Commun201749113413928711493
   PubMed Web of Science ®Google Scholar
• ZhangJLaiWLiQA novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC modelsBiochem Biophys Res Commun201749146947728698142
   PubMed Web of Science ®Google Scholar
• Sato-DahlmanMMiuraYHuangJLCD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancerOncotarget20178760447605629100290
   PubMedGoogle Scholar
• LiuZYangYZhangXAn oncolytic adenovirus encoding decorin and GM-CSF inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune-activationHum Gene Ther20172866768028530155
   PubMed Web of Science ®Google Scholar
• ShihCSLaurieNHolzmacherJAAV-mediated local delivery of interferon-β for the treatment of retinoblastoma in preclinical modelsNeuromolecular Med200911435219306089
   PubMed Web of Science ®Google Scholar
• LuLLuoSTShiHSAAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expressionOncol Rep2012281332133822824831
   PubMed Web of Science ®Google Scholar
• LingCLuYChengBHigh efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectorsJ Vis Exp201149e2538
   Google Scholar
• YuanLZhaoHZhangLLiuXThe efficacy of combination therapy using adeno-associated virus co-expression of apoptin and interleukin-24 on hepatocellular carcinomaTumour Biol2013343027303423907578
   PubMed Web of Science ®Google Scholar
• SuHChangJCXuSMKanYWSelective killing of AFP positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase geneHum Gene Ther199674634708800740
   PubMed Web of Science ®Google Scholar
• SteeleJCDi PasqualeGRamloganCAPatelVChioriniJAMorrisJCOral vaccination with adeno-associated virus vectors expressing the Neu inhibits the growth of murine breast cancerMol Ther20132168068723295951
   PubMed Web of Science ®Google Scholar
• SunATangJTerranovaPFZhangXThrasherJBLiBAdeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical studyInt J Cancer201012676477419642108
   PubMed Web of Science ®Google Scholar
• CrommentuijnMHKantarRNoskeDPSystemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft modelMol Ther Oncolytics201631601727382645
   PubMed Web of Science ®Google Scholar
• ZhenZYangKYeLYouZChenRLiuYDecorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1Invest New Drugs Epub2017620
   Web of Science ®Google Scholar
• MeshiiNTakahashiGOkunagaSEnhancement of systemic tumor immunity for squamous cell carcinoma cells from oncolytic herpes simplex virusCancer Gene Ther20132049349823887644
   PubMed Web of Science ®Google Scholar
• LiHNakashimaHDeckleverTDNaceRARussellSJHSV-NIS, an oncolytic herpes simplex virus type 1 encoding the human sodium iodine symporter for preclinical prostate cancer radiovirotherapyCancer Gene Ther20132047848523868101
   PubMed Web of Science ®Google Scholar
• ChenCYWangPYHutzenBCooperation of oncolytic herpes virotherapy and blockade in murine rhabdomyosarcoma modelsSci Rep20177239628539588
   PubMed Web of Science ®Google Scholar
• YinLZhaoCHanJAntitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivoTher Clin Risk Manag20171311713028223815
   PubMed Web of Science ®Google Scholar
• DelwarZMLiuGKuoYTumour-specific triple-regulated oncolytic herpes virus to target gliomaOncotarget20167286582866927070093
   PubMedGoogle Scholar
• EsakiSRabkinSDMartuzaRLWakimotoHTransient fasting enhances replication of oncolytic herpes simplex virus in glioblastomaAm J Cancer Res2016630031127186404
   PubMed Web of Science ®Google Scholar
• KharePDLiaoSHiroseYTumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS geneAnticancer Res2002222443244612174941
   PubMed Web of Science ®Google Scholar
• LiFGuoYHanLIn vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirusOncol Lett201241254125823205123
   PubMed Web of Science ®Google Scholar
• SchambachAMorganMRetroviral vectors for cancer gene therapyRecent Results Cancer Res2016209173528101685
   PubMedGoogle Scholar
• LuYCChenYJYuYRReplicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinomaOncol Rep201228212622552490
   PubMed Web of Science ®Google Scholar
• LoggCRRobbinsJMJollyDJGruberHEKasaharaNRetroviral replicating vectors in cancerMethods Enzymol201250719922822365776
   PubMed Web of Science ®Google Scholar
• XiaoLJooKILimMWangPDendritic cell-directed vaccination with a lentivector PSCA for prostate cancer in micePLoS One20127e4886623139820
   PubMed Web of Science ®Google Scholar
• RavetLLulkaHGrossFCasteillaLBuscailLCordelierPUsing lentiviral vectors for efficient pancreatic cancer gene therapyCancer Gene Ther20101731532419911032
   PubMed Web of Science ®Google Scholar
• ZhangYWNiuJLuXMulti-target lentivirus specific to hepatocellular carcinoma: in vitro and in vivo studiesJ Hepatol20135850250823149065
   PubMed Web of Science ®Google Scholar
• ChenYSLiHRMiaoYLocal injection of lentivirus-delivered livin shRNA suppresses lung adenocarcinoma growth by inducing a G0/G1-phase cell cycle arrestInt J Clin Exp Pathol2012579680523071862
   PubMed Web of Science ®Google Scholar
• LiRYangHQHiHLFengSQinRHInhibition of CDH17 gene expression via RNA interference reduces proliferation and apoptosis of human MKN28 gastric cancer cellsInt J Oncol201750152227909714
   PubMed Web of Science ®Google Scholar
• YanFWangXZhuMHuXRNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growthOncol Rep2016362793279927666310
   PubMed Web of Science ®Google Scholar
• TianLLiuJXiaGHChenBARNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemiaMed Oncol2017342128058629
   PubMed Web of Science ®Google Scholar
• YolamanovaMMeierCShaytanAKPeptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating virusesNat Nanotechnol2013813013623334171
   PubMed Web of Science ®Google Scholar
• RanzaniMCesanaDBartolomaeCCLentiviral vector-based insertional mutagenesis identifies genes associated with liver cancerNat Methods20131015516123314173
   PubMed Web of Science ®Google Scholar
• UhligKMSchülkeSScheupleinVALentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell responseJ Virol2015899044906026085166
   PubMed Web of Science ®Google Scholar
• LiljeströmPGaroffHA new generation of animal cell expression vectors based on the Semliki Forest virus repliconBiotechnology (N Y)19919135613611370252
   PubMedGoogle Scholar
• XiongCLevisRShenPSchlesingerSRiceCMHuangHVSindbis virus: an efficient, broad host range vector for gene expression in animal cellsScience1989243118811912922607
   PubMed Web of Science ®Google Scholar
• DavisNLWillisLVSmithJFJohnstonREIn vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutantVirology19891711892042525837
   PubMed Web of Science ®Google Scholar
• YingHZaksTZWangRFCancer therapy using a self-replicating RNA vaccineNat Med1999582382710395329
   PubMed Web of Science ®Google Scholar
• MurphyAMMorris-DownesMMSheahanBJAtkinsGJInhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particlesGene Ther200071477148211001367
   PubMed Web of Science ®Google Scholar
• LeitnerWWHwangLNdeVeerMJAlphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathwaysNat Med20039333912496961
   PubMed Web of Science ®Google Scholar
• Vähä-KoskelaMJKallioJPJanssonLCOncolytic capacity of attenuated replicative Semliki Forest virus in human melanoma xenografts in severe combined immunodeficient miceCancer Res2006667185719416849565
   PubMed Web of Science ®Google Scholar
• KetolaAHinkkanenAYongabiFOncolytic Semliki Forest virus vector as a novel candidate against unresectable osteosarcomaCancer Res2008688342835018922906
   PubMed Web of Science ®Google Scholar
• MäättäAMMäkinenKKetolaAReplication competent Semliki Forest virus prolongs survival in experimental lung cancerInt J Cancer20081231704171118651570
   PubMed Web of Science ®Google Scholar
• AutioKPRuotsalainenJJAnttilaMOAttenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory beaglesBMC Vet Res20151117026215394
   PubMed Web of Science ®Google Scholar
• TsengJCLevinBHurtadoASystemic tumor targeting and killing by Sindbis viral vectorsNat Biotechnol200422707714647305
   PubMed Web of Science ®Google Scholar
• Rodriguez-MadozJRPrietoJSmerdouCBiodistribution and tumor infectivity of Semliki Forest virus vectors in mice: effects of re-administrationMol Ther2007152164217117667947
   PubMed Web of Science ®Google Scholar
• LundstromKBoulikasTBreakthrough in cancer therapy: encapsulation of drugs and virusesCurr Drug Discov2002111923
   Google Scholar
• YlösmäkiEMartikainenMHinkkanenASakselaKAttenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargetingJ Virol20138733534423077310
   PubMed Web of Science ®Google Scholar
• LinYZhangHLiangJIdentification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancersProc Natl Acad Sci U S A2014111E4504E451225288727
   PubMed Web of Science ®Google Scholar
• ZhangHLinYLiKNaturally existing oncolytic virus M1 Is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injectionsHum Gene Ther20162770071127296553
   PubMed Web of Science ®Google Scholar
• MartikainenMRuotsalainenJTuomelaJOncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in miceBr J Cancer2017117515528557974
   PubMed Web of Science ®Google Scholar
• PijlmanGPSuhrbierAKhromykhAAKunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applicationsExp Opin Biol Ther20066134145
   Web of Science ®Google Scholar
• ShiPYTilgnerMLoMKConstruction and characterization of subgenomic replicons of New York strain of West Nile virusVirology200229621923312069521
   PubMed Web of Science ®Google Scholar
• MolenkampRKooiEALucassenMAYellow fever virus replicons as an expression system for hepatitis C virus structural proteinsJ Virol2003771644164812502883
   PubMed Web of Science ®Google Scholar
• JonesMDavidsonAHibbertLDengue virus inhibits alpha interferon signaling by reducing STAT2 expressionJ Virol2005795414542015827155
   PubMed Web of Science ®Google Scholar
• GherkeREckerMAberleSWAllisonSLHeinzFXMandlCWIncorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell lineJ Virol2003778924893312885909
   PubMed Web of Science ®Google Scholar
• Hoang-LeDSmeenkLAnrakuIA Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intratumoral gene therapyGene Ther20091619019919092857
   PubMed Web of Science ®Google Scholar
• OsakadaFCallawayEMDesign and generation of recombinant rabies virus vectorsNat Protoc201381583160123887178
   PubMed Web of Science ®Google Scholar
• ItoNTakayama-ItoMYamadaKHosokawaJSugiyamaMMinamotoNImproved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics systemMicrobiol Immunol20034761361714524622
   PubMed Web of Science ®Google Scholar
• AnHKimGNKangCYGenetically modified VSVNJ vector is capable of accommodating a large foreign gene insert and allows high level gene expressionVirus Res201317116817723207069
   PubMed Web of Science ®Google Scholar
• MurphyAMBesmerDMMoerdyk-SchauweckerMVesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinomaJ Virol2012863073308722238308
   PubMed Web of Science ®Google Scholar
• HastieEBesmerDMShahNROncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive of MUC1-null pancreatic ductal adenocarcinomaJ Virol201387102831029423864625
   PubMed Web of Science ®Google Scholar
• HastieEGrdzelishviliVZVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerJ Gen Virol2012932529254523052398
   PubMed Web of Science ®Google Scholar
• FeltSAMoerdyk-SchauweckerMJGrdzelishviliVZInduction of apoptosis in pancreatic cancer cells by vesicular stomatitis virusVirology201547416317325463614
   PubMed Web of Science ®Google Scholar
• Le BoeufFSelmanMSonHHOncolytic Maraba virus MG1 as a treatment for sarcomaInt J Cancer20171411257126428568891
   PubMed Web of Science ®Google Scholar
• ZhouYWenFZhangPTangRLiQVesicular stomatitis virus is a potent agent for the treatment of malignant ascitesOncol Rep2016351573158126707610
   PubMed Web of Science ®Google Scholar
• RadeckeFSpielhoferPSchneiderHRescue of measles viruses from cloned DNAEMBO J199514577357848846771
   PubMed Web of Science ®Google Scholar
• MsaouelPIankovIDDispenzieriAGalanisEAttenuated oncolytic measles virus strains as cancer therapeuticsCurr Pharm Biotechnol2012131732174121740361
   PubMed Web of Science ®Google Scholar
• GroteDRussellSJCornuTILive attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient miceBlood2001973746375411389012
   PubMed Web of Science ®Google Scholar
• HasegawaKPhamLO’ConnorMKFederspielMJRussellSJPengKWDual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporterClin Cancer Res2006121868187516551872
   PubMed Web of Science ®Google Scholar
• McDonaldCJErlichmanCIngleJNA measles virus vaccine strain derivative as a novel oncolytic agent against breast cancerBreast Cancer Res Treat20069917718416642271
   PubMed Web of Science ®Google Scholar
• MsaouelPIankovIDAllenCEngineered measles virus as a novel oncolytic therapy against prostate cancerProstate200969829118973133
   PubMed Web of Science ®Google Scholar
• ParaskevakouGAllenCNakamuraTEpidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomasMol Ther20071567768617299404
   PubMed Web of Science ®Google Scholar
• KleinlützumDHanauerJDMuikAEnhancing the oncolytic activity of CD133-targeted measles virus: receptor extension or chimerism with vesicular stomatitis virus are most effectiveFront Oncol2017712728695108
   PubMed Web of Science ®Google Scholar
• VeinaldeRGrossardtCHartmannLOncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activationOncoimmunology20176e128599228507792
   PubMed Web of Science ®Google Scholar
• CsataryLKMossRWBeuthHTöröcsikBSzeberenyiJBakacsTBeneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MHT-68/H)Anticancer Res19991963563810216468
   PubMed Web of Science ®Google Scholar
• ZhaoLLiuHNewcastle disease virus: a promising agent for tumor immunotherapyClin Exp Pharmacol Physiol20123972573022211810
   PubMed Web of Science ®Google Scholar
• NiuZBaiFSunTRecombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma modelTechnol Cancer Res Treat20151460761524645750
   PubMed Web of Science ®Google Scholar
• ChaiZZhangPFuFOncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancerVirol J2014118424885546
   PubMed Web of Science ®Google Scholar
• KumarRTiwariAKChaturvediUVelogenic Newcastle disease virus as an oncolytic virotherapeutics: in vitro characterizationAppl Biochem Biotechnol20121672005202222644640
   PubMed Web of Science ®Google Scholar
• WuYHeJAnYRecombinant Newcastle disease virus (NDV/ANH-IL-2) expressing human IL-2 as a potential candidate suppresses growth of hepatoma therapyJ Pharmacol Sci2016132243027174862
   PubMed Web of Science ®Google Scholar
• WuYHeJGengJRecombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapyEur J Pharmacol2017802859228246027
   PubMed Web of Science ®Google Scholar
• ChengXWangWXuQGenetic modification of oncolytic New-castle disease virus for cancer therapyJ Virol2016905343535227009956
   PubMed Web of Science ®Google Scholar
• CasselWAMurrayDRA ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysateMed Oncol Tumor Pharmacother199291691711342060
   PubMedGoogle Scholar
• SteinerHHBonsantoMMBeckhovePAntitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefitJ Clin Oncol2004224272428115452186
   PubMed Web of Science ®Google Scholar
• Herold-MendeCKarcherJDyckhoffGSchirrmacherVAntitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccineAdv Otorhinolaryngol20056217318315608427
   PubMedGoogle Scholar
• ZehHJBartlettDLDevelopment of a replication-selective oncolytic poxvirus for the treatment of human cancersCancer Gene Ther200291001101212522439
   PubMed Web of Science ®Google Scholar
• MastrangeloMJLattimeECVirotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectorsCancer Gene Ther200291013102112522440
   PubMed Web of Science ®Google Scholar
• ChenBTimiryasovaTMHaghighatPLow-dose vaccinia virus-mediated cytokine gene therapy of gliomaJ Immunother200124465711211148
   PubMed Web of Science ®Google Scholar
• EhrigKKilincMOChenNGGrowth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68J Transl Med2013117923531320
   PubMed Web of Science ®Google Scholar
• ChernichenkoNLinkovGLiPOncolytic vaccinia virus therapy of salivary gland carcinomaJAMA Otolaryngol Head Neck Surg201313917318223429949
   PubMed Web of Science ®Google Scholar
• HaddadDChenNZhangQA novel genetically modified vaccinia virus in experimental models is effective against a wide range of human cancersAnn Surg Oncol201219Suppl 3S665S67422258815
   PubMed Web of Science ®Google Scholar
• BinzEBerchtoldSBeilJChemovirotherapy of pancreatic adenocarcinoma by combining oncolytic vaccinia virus GLV-1h68 with nab-paclitaxel plus gemcitabineMol Ther Oncolytics20176102128607950
   PubMed Web of Science ®Google Scholar
• BrunJMahoneyDJLe BoeufFOncolytic vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosumInt J Cancer201313272673122733395
   PubMed Web of Science ®Google Scholar
• MellLKBrumundKTDanielsGAPhase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinomaClin Cancer Res2017235696570228679776
   PubMed Web of Science ®Google Scholar
• CrainicRCoudercTMartinAWychowskiCGirardMHoraudFAn insight into poliovirus biologyAdv Exp Med Biol198925761662482671
   PubMedGoogle Scholar
• BradleySJakesADHarringtonKPandhaHMelcherAErrington-MaisFApplications of coxsackievirus A21 in oncologyOncolytic Virother20143475527512662
   PubMedGoogle Scholar
• ShafrenDRAuGGNguyenTSystemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21Clin Cancer Res200410536014734451
   PubMed Web of Science ®Google Scholar
• AuGGLinczLFEnnoAShafrenDROncolytic coxsackievirus A21 as a novel therapy for multiple myelomaBr J Haematol200713713314117391493
   PubMed Web of Science ®Google Scholar
• SkeldingKABarryRDShafrenDRSystemic targeting of metastatic human breast tumor xenografts by coxsackievirus A21Breast Cancer Res Treat2009113213018256929
   PubMed Web of Science ®Google Scholar
• BerryLJAuGGBarryRDPotent oncolytic activity of human enteroviruses against human prostate cancerProstate20086857758718288643
   PubMed Web of Science ®Google Scholar
• YeeYWChanSHQuahMYShafrenDROncolytic activity of coxsackievirus A21 (CAVATAK) in human lung cancer: a novel targeted anti-cancer strategyPoster presented at: 14th World Conference on Lung CancerJuly 3–7, 2011Amsterdam, Netherlands
   Google Scholar
• BreitbachCJDe SilvaNSFallsTJTargeting tumor vasculature with an oncolytic virusMol Ther20111988689421364541
   PubMed Web of Science ®Google Scholar
• BenenciaFCourregesMCConejo-GarciaJROncolytic HSV exerts direct antiangiogenic activity in ovarian carcinomaHum Gene Ther20051676577815960607
   PubMed Web of Science ®Google Scholar
• BreitbachCJArulanandamRDe SilvaNOncolytic vaccinia virus disrupts tumor-associated vasculature in humansCancer Res2013731265127523393196
   PubMed Web of Science ®Google Scholar
• ZhangZZouWWangJSuppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1Mol Ther20051155356215771958
   PubMed Web of Science ®Google Scholar
• GholamiSMaranoAChenNGA novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancerBreast Cancer Res Treat201414848949925391896
   PubMed Web of Science ®Google Scholar
• HouWZChenHRojasJSampathPThorneSHOncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGFInt J Cancer20141351238124624474587
   PubMed Web of Science ®Google Scholar
• JhaBKPolyakovaIKesslerPInhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunityJ Biol Chem2011286263192632621636578
   PubMed Web of Science ®Google Scholar
• JhaBKDongBNguyenCTPolyakovaISilvermanRHSuppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapyMol Ther2013211749175723732991
   PubMed Web of Science ®Google Scholar
• PassaroCBorrielloFVastoloVThe oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinomaOncotarget201671500151526625205
   PubMed Web of Science ®Google Scholar
• TaguchiSFukuharaHHommaYTodoTCurrent status of clinical trials assessing oncolytic virus therapy for urological cancersInt J Urol20172434235128326624
   PubMed Web of Science ®Google Scholar
• BurkeJMLammDLMengMVA first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancerJ Urol20121882391239723088985
   PubMed Web of Science ®Google Scholar
• SmallEJCarducciMABurkeJMA phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerMol Ther20061410711716690359
   PubMed Web of Science ®Google Scholar
• FreytagSOKhilMStrickerHPhase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancerCancer Res2002624968497612208748
   PubMed Web of Science ®Google Scholar
• PecoraALRizviNCohenGIPhase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancersJ Clin Oncol2002202251226611980996
   PubMed Web of Science ®Google Scholar
• ParkBHHwangTLiuTCUse of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialLancet Oncol2008953354218495536
   PubMed Web of Science ®Google Scholar
• KimSGHwangTHPhase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC)Eur J Cancer201551S510
   Web of Science ®Google Scholar
• GomellaLGMastrangeloMJMcCuePAMaguireHCMulhollandSGLattimeECPhase 1 study of intravesical vaccinia virus as a vector for gene therapy of bladder cancerJ Urol20011661291129511547060
   PubMed Web of Science ®Google Scholar
• GulleyJLHeeryCRMadanRAPhase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancerCancer Immunol Immunother2013621521153123836412
   PubMed Web of Science ®Google Scholar
• VidalLPandhaHSYapTAA phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancerClin Cancer Res2008147127713718981012
   PubMed Web of Science ®Google Scholar
• NoonanAMFarrenMRGeyerSMRandomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinomaMol Ther2016241150115827039845
   PubMed Web of Science ®Google Scholar
• GalanisEMarkovicSNSumanVJPhase II trial of intravenous administration of Reolysin (reovirus serotype-3-dearing strain) in patients with metastatic melanomaMol Ther2012201998200322871663
   PubMed Web of Science ®Google Scholar
• KarapanaglotouEMRoulstoneVTwiggerKPhase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesClin Cancer Res2012182080208922316603
   PubMed Web of Science ®Google Scholar
• PatelDMForemanPMNaborsLBRileyKGillespieYMarkertJDesign of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcomaHum Gene Ther Clin Dev201627697827314913
   PubMed Web of Science ®Google Scholar
• RothJCCassadyKACodyJJEvaluation of the safety and biodistribution of M032 an attenuated herpes simplex virus type 1 expressing hIL-12 after intracerebral administration of Aotus nonhuman primatesHum Gene Ther Clin Dev201425162724649838
   PubMed Web of Science ®Google Scholar
• MarkertJMRazdanSNKuoHCA phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responsesMol Ther2014221048105524572293
   PubMed Web of Science ®Google Scholar
• MarkertJMLiechtyPGWangWPhase 1B trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBMMol Ther20091719920718957964
   PubMed Web of Science ®Google Scholar
• SlovinSFKehoeMDursoRA phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancerVaccine20133194394923246260
   PubMed Web of Science ®Google Scholar
• PandhaHHarringtonKRalphCMelcherAGroseMShafrenDPhase I/II storm study: intravenous delivery of a novel oncolytic immunotherapy agent, coxsackievirus A21, in advanced cancer patientsJ Immunother Cancer20153P341
   Google Scholar
• AndtbackaRHCurtiBDHallmeyerSPhase II calm extension study: coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironmentJ Immunother Cancer20153P343
   Google Scholar
• SilkAWKaufmanHGabrielNPhase 1B study of intratumoral coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: interim results of the CAPRA clinical trialCancer Res201777CT026
   Web of Science ®Google Scholar
• RätyJKPikkarainenJTWirthTGene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indicationsCurr Mol Pharmacol20081132320021420
   PubMedGoogle Scholar
• LiuTCKimDGene therapy progress and prospects cancer: oncolytic virusesGene Ther20081587788418418413
   PubMed Web of Science ®Google Scholar
• FukuharaHInoYTodoTOncolytic virus therapy: a new era of cancer treatment at dawnCancer Sci20161071373137927486853
   PubMed Web of Science ®Google Scholar
• KaufmanHLKimDWDeRaffeleGMitchamJCoffinRSKim-SchulzeSLocal and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIC and IV melanomaAnn Surg Oncol20101771873019915919
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med20131932933623396206
   PubMed Web of Science ®Google Scholar
• InoYTodoTClinical development of a third-generation HSV-1 (G47δ) for malignant gliomaGene Ther Regul20105101111
   Google Scholar
• RameshNGeYEnnistDLCG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancerClin Cancer Res20061230531316397056
   PubMed Web of Science ®Google Scholar
• GollamudiRGhalibMHDesaiKKIntravenous administration of Reolysin, a live replication competent RNA virus is safe in patients in advanced solid tumorsInvest New Drugs20102864164919572105
   PubMed Web of Science ®Google Scholar